Walleye Capital
NTLA icon

Walleye Capital’s Intellia Therapeutics NTLA Stock Holding History

Walleye Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.99K Buy
+413
New +$5.78K ﹤0.01% 4518
2026
Q1 		– Sell
-6,580
Closed -$83.8K – 4792
2025
Q4 		$59.2K Buy
+6,580
New +$90.6K ﹤0.01% 4041
2025
Q3 		– Sell
-29,948
Closed -$369K – 4924
2025
Q2 		$281K Sell
29,948
-11,524
-28% -$94.6K ﹤0.01% 3095
2025
Q1 		$295K Sell
41,472
-142,600
-77% -$1.44M ﹤0.01% 2970
2024
Q4 		$2.15M Buy
184,072
+113,043
+159% +$1.76M 0.01% 1724
2024
Q3 		$1.46M Buy
71,029
+15,874
+29% +$366K ﹤0.01% 2258
2024
Q2 		$1.23M Buy
55,155
+49,647
+901% +$1.18M ﹤0.01% 2615
2024
Q1 		$152K Sell
5,508
-197,819
-97% -$5.49M ﹤0.01% 4153
2023
Q4 		$6.2M Buy
203,327
+19,872
+11% +$571K 0.01% 965
2023
Q3 		$5.8M Buy
+183,455
New +$7.12M 0.01% 922
2023
Q2 		– Sell
-127,504
Closed -$5.17M – 4713
2023
Q1 		$4.75M Buy
127,504
+32,080
+34% +$1.26M 0.07% 344
2022
Q4 		$3.33M Buy
95,424
+77,163
+423% +$3.67M 0.06% 383
2022
Q3 		$1.02M Buy
+18,261
New +$1.13M 0.02% 950
2022
Q2 		– Sell
-50,521
Closed -$3.67M – 2610
2022
Q1 		$3.67M Buy
50,521
+43,147
+585% +$3.66M 0.1% 219
2021
Q4 		$872K Buy
+7,374
New +$924K 0.03% 674
2020
Q2 		– Sell
-1,485
Closed -$18K – 858
2020
Q1 		$18K Sell
1,485
-1,112
-43% -$15K ﹤0.01% 761
2019
Q4 		$38K Sell
2,597
-924
-26% -$12.9K ﹤0.01% 1543
2019
Q3 		$47K Buy
+3,521
New +$56.1K ﹤0.01% 1617

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Walleye Capital's NTLA Position: Q2 2026 in Review

Walleye Capital opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 413 shares worth $6.99K. The stake represents ﹤0.01% of the portfolio and ranks #4518 among its holdings. This is a return to the name: Walleye Capital previously reported a position in NTLA as recently as Q4 2025.

Walleye Capital first reported a position in NTLA in Q3 2019 and has held it in 18 quarters since. The position peaked at $6.2M in Q4 2023. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Walleye Capital held 413 shares of Intellia Therapeutics worth $6.99K as of Q2 2026.
  • Intellia Therapeutics was a new Walleye Capital position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4518 holding.
  • Walleye Capital first reported a position in Intellia Therapeutics in Q3 2019 and has held it in 18 quarters since.
  • Walleye Capital's Intellia Therapeutics position peaked at $6.2M in Q4 2023.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.